Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter Randomized Controlled Open-label Study of Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

NCT06241781 is registered in ClinicalTrials.gov with Grit Biotechnology as lead sponsor.

NCT NCT06241781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06241781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter Randomized Controlled Open-label Study of Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
Lead sponsor
Grit Biotechnology
Phase
Phase 2
Overall status
Recruiting
Start date
April 2, 2024
Completion date
January 31, 2027
Enrollment
83 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

adult